SCHEMBL1342065

SCHEMBL1342065

Cn1nnnc1Sc1sc(NC(=O)Nc2ccncc2C(=O)C2CCCC2)nc1CC(=O)O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.34
NPC1 O15118 6/20 0.34
CCNE1 P24864 2/20 0.33
CDK2 P24941 2/20 0.33
CDK5 Q00535 2/20 0.33
GAA P10253 3/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA9 Q16790 1/20 0.32
ALDH1A1 P00352 2/20 0.32
ALOX15 P16050 1/20 0.31
HSD17B10 Q99714 1/20 0.31
MAPT P10636 2/20 0.31
KDM4E B2RXH2 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.30
LMNA P02545 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1341563 0.95 RAB9A (0.34) RAB9ANPC1CCNE1CDK2CDK5
SCHEMBL1342032 0.91 ALDH1A1 (0.39) RAB9ANPC1GAAALDH1A1ALOX15
SCHEMBL1341741 0.89 NPC1 (0.36) RAB9ANPC1CCNE1CDK2CDK5
SCHEMBL1342428 0.89 CA12 (0.34) RAB9ANPC1CCNE1CDK2CDK5
SCHEMBL1341705 0.88 CCNE1 (0.34) RAB9ANPC1CCNE1CDK2CDK5
SCHEMBL1342757 0.88 LMNA (0.40) RAB9ANPC1GAASMN1; SMN2ALDH1A1
SCHEMBL1341982 0.87 LMNA (0.34) RAB9ANPC1GAASMN1; SMN2ALDH1A1
SCHEMBL1340449 0.87 MAPT (0.36) RAB9ANPC1GAASMN1; SMN2ALDH1A1
SCHEMBL1341891 0.86 MAPT (0.42) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL1342042 0.86 RAB9A (0.33) RAB9ANPC1GAASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 RAB9A 3353/4885NPC1 2201/4885CCNE1 4257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.